The announcement follows the decision to discontinue the COAST and ShORe trials in wet age-related macular degeneration after ...

Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech ...

The ASX has been up, charging 4.7% higher at around 7,720 points today. Sayona Mining (ASX:SYA) has been among the most ...

In the wake of failed late-stage clinical trials last month for its novel retinal disease therapy, Melbourne-headquartered ...

Regal Partners has written off its entire investment in Opthea, which contributed to funds under management (FUM) taking an 8.3% hit in the March 2025 quarter.

Troubled biotech stock Opthea (ASX:OPT), still in the process of crisis talks with investors, has flagged a workforce ...